Pranlukast inhibits renal epithelial cyst progression via activation of AMP-activated protein kinase

European Journal of Pharmacology

Volumn 724, Issue 1, 2014, Pages 67-76

  Pathomthongtaweechai, Nutthapoom ^a   Soodvilai, Sunhapas ^a   Chatsudthipong, Varanuj ^a   Muanprasat, Chatchai ^a  

^a Mahidol University   (Thailand)

Author keywords

AMPK; CFTR; mTOR; Polycystic kidney disease; Pranlukast

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE BETA; CHLORIDE; CYCLIC AMP; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MONTELUKAST; PRANLUKAST; UNCLASSIFIED DRUG; ZAFIRLUKAST;

ANIMAL CELL; ARTICLE; CANINE MODEL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; IMMUNOBLOTTING; KIDNEY CELL; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

AMPK; CFTR; MTOR; POLYCYSTIC KIDNEY DISEASE; PRANLUKAST;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CHLORIDES; CHROMONES; COLFORSIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTS; DOGS; EPITHELIAL CELLS; KIDNEY; LEUKOTRIENE ANTAGONISTS; MADIN DARBY CANINE KIDNEY CELLS; POLYCYSTIC KIDNEY DISEASES; RECEPTORS, LEUKOTRIENE;

EID: 84891808866     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.12.013     Document Type: Article

References (33)

1. N.C. Barnes, B. de Jong, and T. Miyamoto Worldwide clinical experience with the first marketed leukotriene receptor antagonist Chest 111 1997 52S 60S (Pubitemid 27100618)
2. J.M. Cacicedo, N. Yagihashi, J.F. Keaney Jr., N.B. Ruderman, and Y. Ido AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells Biochem. Biophys. Res. Commun. 324 2004 1204 1209 (Pubitemid 40292150)
3. Y. Chi, K. Li, Q. Yan, S. Koizumi, L. Shi, S. Takahashi, Y. Zhu, H. Matsue, M. Takeda, M. Kitamura, and J. Yao Nonsteroidal anti-inflammatory drug flufenamic acid is a potent activator of AMP-activated protein kinase J. Pharmacol. Exp. Ther. 339 2011 257 266
4. S. Chung, H. Yao, S. Caito, J.W. Hwang, G. Arunachalam, and I. Rahman Regulation of SIRT1 in cellular functions: role of polyphenols Arch. Biochem. Biophys. 501 2010 79 90
5. C. Fukushima, H. Matsuse, Y. Hishikawa, Y. Kondo, I. Machida, S. Saeki, T. Kawano, S. Tomari, Y. Obase, T. Shimoda, T. Koji, and S. Kohno Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism Int. Arch. Allergy Appl. Immunol. 136 2005 165 172 (Pubitemid 40463242)
6. A. Gormand, E. Henriksson, K. Strom, T.E. Jensen, K. Sakamoto, and O. Goransson Regulation of AMP-activated protein kinase by LKB1 and CaMKK in adipocytes J. Cell. Biochem. 112 2011 1364 1375
7. K.R. Hallows, V. Raghuram, B.E. Kemp, L.A. Witters, and J.K. Foskett Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase J. Clin. Invest. 105 2000 1711 1721 (Pubitemid 30421752)
8. D.G. Hardie, F.A. Ross, and S.A. Hawley AMPK: a nutrient and energy sensor that maintains energy homeostasis Nat. Rev. Mol. Cell Biol. 13 2012 251 262
9. T. Ichiyama, S. Hasegawa, M. Umeda, K. Terai, T. Matsubara, and S. Furukawa Pranlukast inhibits NF-kappa B activation in human monocytes/ macrophages and T cells Clin. Exp. Allergy (Journal of the British Society for Allergy and Clinical Immunology) 33 2003 802 807 (Pubitemid 36760513)
10. P. Igarashi, and S. Somlo Genetics and pathogenesis of polycystic kidney disease J. Am. Soc. Nephrol.: JASN 13 2002 2384 2398 (Pubitemid 34925250)
11. H. Ishinaga, K. Takeuchi, C. Kishioka, S. Suzuki, C. Basbaum, and Y. Majima Pranlukast inhibits NF-kappaB activation and MUC2 gene expression in cultured human epithelial cells Pharmacology 73 2005 89 96 (Pubitemid 40082319)
12. A.S. Kahnt, F. Rorsch, O. Diehl, B. Hofmann, C. Lehmann, S.D. Steinbrink, C. Angioni, G. Geisslinger, S. Grosch, D. Steinhilber, and T.J. Maier Cysteinyl leukotriene-receptor-1 antagonists interfere with PGE2 synthesis by inhibiting mPGES-1 activity Biochem. Pharmacol. 86 2013 286 296
13. H.J. Kim, K.G. Park, E.K. Yoo, Y.H. Kim, Y.N. Kim, H.S. Kim, H.T. Kim, J.Y. Park, K.U. Lee, W.G. Jang, J.G. Kim, B.W. Kim, and I.K. Lee Effects of PGC-1alpha on TNF-alpha-induced MCP-1 and VCAM-1 expression and NF-kappaB activation in human aortic smooth muscle and endothelial cells Antioxidants Redox Signal. 9 2007 301 307 (Pubitemid 46150964)
14. W.K. Lau, A.W. Chow, S.C. Au, and W.H. Ko Differential inhibitory effects of CysLT(1) receptor antagonists on P2Y(6) receptor-mediated signaling and ion transport in human bronchial epithelia PLoS One 6 2011 e22363
15. H. Li, I.A. Findlay, and D.N. Sheppard The relationship between cell proliferation, Cl-secretion, and renal cyst growth: a study using CFTR inhibitors Kidney Int. 66 2004 1926 1938 (Pubitemid 41094317)
16. X. Li, B.S. Magenheimer, S. Xia, T. Johnson, D.P. Wallace, J.P. Calvet, and R. Li A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease Nat. Med. 14 2008 863 868
17. Y.C. Liu, A.M. Khawaja, and D.F. Rogers Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitro Br. J. Pharmacol. 124 1998 563 571 (Pubitemid 28254514)
18. T. Mochizuki, K. Tsuchiya, and K. Nitta Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies Clin. Exp. Nephrol. 17 2013 317 326
19. C. Muanprasat, L. Sirianant, S. Soodvilai, R. Chokchaisiri, A. Suksamrarn, and V. Chatsudthipong Novel action of the chalcone isoliquiritigenin as a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor: potential therapy for cholera and polycystic kidney disease J. Pharmacol. Sci. 118 2012 82 91
20. S. Omori, M. Hida, H. Fujita, H. Takahashi, S. Tanimura, M. Kohno, and M. Awazu Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease J. Am. Soc. Nephrol.: JASN 17 2006 1604 1614 (Pubitemid 43794663)
21. S.J. Park, F. Ahmad, A. Philp, K. Baar, T. Williams, H. Luo, H. Ke, H. Rehmann, R. Taussig, A.L. Brown, M.K. Kim, M.A. Beaven, A.B. Burgin, V. Manganiello, and J.H. Chung Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases Cell 148 2012 421 433
22. I. Rowe, M. Chiaravalli, V. Mannella, V. Ulisse, G. Quilici, M. Pema, X.W. Song, H. Xu, S. Mari, F. Qian, Y. Pei, G. Musco, and A. Boletta Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy Nat. Med. 19 2013 488 493
23. H.M. Sarau, R.S. Ames, J. Chambers, C. Ellis, N. Elshourbagy, J.J. Foley, D.B. Schmidt, R.M. Muccitelli, O. Jenkins, P.R. Murdock, N.C. Herrity, W. Halsey, G. Sathe, A.I. Muir, P. Nuthulaganti, G.M. Dytko, P.T. Buckley, S. Wilson, D.J. Bergsma, and D.W. Hay Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor Mol. Pharmacol. 56 1999 657 663 (Pubitemid 29406893)
24. J. Shan, J. Huang, J. Liao, R. Robert, and J.W. Hanrahan Anion secretion by a model epithelium: more lessons from Calu-3 Acta Physiol. (Oxford) 202 2011 523 531
25. J.M. Shillingford, N.S. Murcia, C.H. Larson, S.H. Low, R. Hedgepeth, N. Brown, C.A. Flask, A.C. Novick, D.A. Goldfarb, A. Kramer-Zucker, G. Walz, K.B. Piontek, G.G. Germino, and T. Weimbs The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease Proc. Nat. Acad. Sci. U.S.A. 103 2006 5466 5471
26. J.M. Shillingford, K.B. Piontek, G.G. Germino, and T. Weimbs Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1 J. Am. Soc. Nephrol.: JASN 21 2010 489 497
27. V. Takiar, S. Nishio, P. Seo-Mayer, J.D. King Jr., H. Li, L. Zhang, A. Karihaloo, K.R. Hallows, S. Somlo, and M.J. Caplan Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis Proc. Nat. Acad. Sci. U.S.A. 108 2011 2462 2467
28. S. Terryn, A. Ho, R. Beauwens, and O. Devuyst Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease Biochim. Biophys. Acta 1812 2011 1314 1321
29. Y. Tohda, H. Nakahara, H. Kubo, R. Haraguchi, M. Fukuoka, and S. Nakajima Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma Clin. Exp. Allergy (Journal of the British Society for Allergy and Clinical Immunology) 29 1999 1532 1536 (Pubitemid 29519284)
30. V.E. Torres, and P.C. Harris Autosomal dominant polycystic kidney disease: the last 3 years Kidney Int. 76 2009 149 168
31. D.P. Wallace Cyclic AMP-mediated cyst expansion Biochim. Biophys. Acta 1812 2011 1291 1300
32. K. Yamauchi, Y. Tanifuji, L.H. Pan, T. Yoshida, S. Sakurai, S. Goto, S. Kuroda, H. Kobayashi, and H. Inoue Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics J. Asthma (Official Journal of the Association for the Care of Asthma) 38 2001 51 57 (Pubitemid 32246194)
33. B. Yang, N.D. Sonawane, D. Zhao, S. Somlo, and A.S. Verkman Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease J. Am. Soc. Nephrol. 19 2008 1300 1310